Sarepta盘后涨近33%！旗下DMD基因疗法Elevidys获批扩展适应症

智通财经06-21

6月21日，生物技术公司Sarepta Therapeutics周四美股盘后大涨近33%。消息面上，美国食品药品管理局(FDA)批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良(DMD)患者纳入其中。FDA对可行走的患者授予了传统批准，对于不可行走的患者则授予加速批准。对不可行走DMD患者的持续批准取决于后续验证性试验的结果。根据加速批准途径，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2445276910?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2024-06-21 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2445276910","market":"us","top_or_hot":-1,"title":"Sarepta盘后涨近33%！旗下DMD基因疗法Elevidys获批扩展适应症","media":"智通财经","content":"<div>\n<p>6月21日，生物技术公司Sarepta Therapeutics周四美股盘后大涨近33%。消息面上，美国食品药品管理局(FDA)批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良(DMD)患者纳入其中。FDA对可行走的患者授予了传统批准，对于不可行走的患者则授予加速批准。对不可行走DMD患者的持续批准取决于后续验证性试验的结果。根据加速批准途径，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1138375.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta盘后涨近33%！旗下DMD基因疗法Elevidys获批扩展适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta盘后涨近33%！旗下DMD基因疗法Elevidys获批扩展适应症\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-21 08:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1138375.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>6月21日，生物技术公司Sarepta Therapeutics周四美股盘后大涨近33%。消息面上，美国食品药品管理局(FDA)批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良(DMD)患者纳入其中。FDA对可行走的患者授予了传统批准，对于不可行走的患者则授予加速批准。对不可行走DMD患者的持续批准取决于后续验证性试验的结果。根据加速批准途径，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1138375.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1138375.html","article_id":"2445276910","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2445276910","pubTimestamp":1718928976,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"S智通财经APP获悉，生物技术公司Sarepta Therapeutics周四美股盘后大涨超33%。消息面上，美国食品药品管理局批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良患者纳入其中。根据加速批准途径，Sarepta承诺进行并提交一项随机对照试验的结果，以验证和确认Elevidys在不可行走DMD患者中的临床益处。罗氏在2019年与Sarepta达成28.5亿美元的研发合作，共同开发这一基因疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SRPT":"Sarepta Therapeutics","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"Sarepta rose nearly 33% after hours! Its DMD gene therapy Elvidys approved for expansion of indications","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/e4f4f84c0db9a1980ffe04199f521544","symbols_score_info":{"SRPT":1},"content_text":"6月21日，生物技术公司Sarepta Therapeutics周四美股盘后大涨近33%。消息面上，美国食品药品管理局(FDA)批准Sarepta与罗氏联合开发的基因疗法Elevidys扩展适应症，将年龄至少为4岁的杜氏肌营养不良(DMD)患者纳入其中。FDA对可行走的患者授予了传统批准，对于不可行走的患者则授予加速批准。对不可行走DMD患者的持续批准取决于后续验证性试验的结果。根据加速批准途径，Sarepta承诺进行并提交一项随机对照试验的结果，以验证和确认Elevidys在不可行走DMD患者中的临床益处。ENVISION(SRP-9001-303)试验正在进行中，这是一项全球性、随机、双盲、安慰剂对照的3期研究，该试验针对不可行走和年龄较大的可行走DMD患者，旨在作为这一上市后要求的验证试验。资料显示，去年6月，Elevidys作为全球首款杜氏肌营养不良(DMD)的一次性基因疗法获得美国FDA批准上市，用于治疗4-5岁可独立行走的DMD患童。Elevidys是一款重组基因疗法，将表达微抗肌萎缩蛋白(micro-dystrophin)的转基因包装在AAV病毒载体中，通过单次静脉注射，使得患者肌肉生成具有部分抗肌萎缩蛋白功能的重组蛋白，可以对携带任何类型DMD致病基因变异的患者生效。罗氏在2019年与Sarepta达成28.5亿美元的研发合作，共同开发这一基因疗法。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445276910"}